What is the dose of Ceftriaxone for community-acquired pneumonia?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 18, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

Community-Acquired Pneumonia Treatment with Ceftriaxone

The recommended dose of Ceftriaxone for community-acquired pneumonia is 1-2 grams administered intravenously every 24 hours 1.

  • The duration of therapy typically ranges from 5 to 7 days, depending on the severity of the infection and the patient's clinical response.
  • In cases of severe community-acquired pneumonia, a dose of 2 grams every 12 hours may be considered, with the treatment course lasting 7 to 10 days. Key considerations for the treatment of community-acquired pneumonia include the severity of illness, pathogen probabilities, resistance patterns of S. pneumoniae, and comorbid conditions 1.
  • For outpatients, administration of a macrolide, doxycycline, or fluoroquinolone with enhanced activity against S. pneumoniae is recommended 1.
  • For patients who are hospitalized, the recommendation is administration of a fluoroquinolone alone or an extended-spectrum cephalosporin (such as ceftriaxone) plus a macrolide 1.
  • Patients hospitalized in the intensive care unit (ICU) should receive ceftriaxone, cefotaxime, ampicillin-sulbactam, or piperacillin-tazobactam in combination with a fluoroquinolone or macrolide 1. The choice of antibiotic and duration of therapy should be guided by clinical response and microbiological results, when available 1.

From the Research

Dose of Ceftriaxone for Community-Acquired Pneumonia

  • The recommended dose of ceftriaxone for community-acquired pneumonia is 1-2 g daily, as stated in various studies 2, 3, 4.
  • A systematic review and meta-analysis found that ceftriaxone dosages of 1 g daily are as safe and effective as other antibiotic regimens for community-acquired pneumonia 2.
  • A retrospective cohort study found that 1 g/d of IV ceftriaxone is associated with similar clinical outcomes to those of 2 g/d, with a decreased rate of C. difficile infection and shorter length of stay 3.
  • Guidelines recommend intravenous (IV) ceftriaxone at a dose of 1-2 g/d as empirical treatment in adults hospitalized with community-acquired pneumonia (CAP), with the addition of macrolide 4.

Specific Patient Groups

  • For patients admitted to general wards with criteria of moderate severity, ceftriaxone 1-2 g once a day or cefotaxime 1 g TID, IV, 7-10 days is recommended 4.
  • For patients with severe CAP that must be interned into ICU, ceftriaxone 2 g once a day or cefotaxime 1 g TID, IV, associated to erythromycin 500 QID, levofloxacin 500-1.000 mg once a day, or moxifloxacin 400 mg/once a day, IV, 10-14 days is recommended 4.

Treatment Duration

  • The treatment duration for community-acquired pneumonia is still under debate, but several studies support short durations of 5-7 days or less 5.
  • Clinical criteria could be possibly used to discontinue antibiotic treatment, and procalcitonin has also been studied as a potential biomarker to guide treatment duration 5.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

[Treatment of community-acquired pneumonia in adults].

Revista chilena de infectologia : organo oficial de la Sociedad Chilena de Infectologia, 2005

Research

Short treatment duration for community-acquired pneumonia.

Current opinion in infectious diseases, 2023

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.